Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifunctional theranostic nanoplatform based on HER2-specific liposomes loaded with IR783 for simultaneous PTT/PDT therapy and optical bioimaging.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same author

Uptake and Retention of Laser-synthesized Boron Nanoparticles in Tumor Cells and Fibroblasts.

Doklady. Biochemistry and biophysics·2026
Same author

The effect of dimeric bisbenzimidazoles on the activity of DNA repair enzymes TDP1, TDP2, PARP1 and PARP2.

Vavilovskii zhurnal genetiki i selektsii·2026
Same author

Synthesis and Pharmacokinetics of Nanosized NH<sub>2</sub>‑UiO‑66 (Zr) Metal-Organic Frameworks.

Doklady. Biochemistry and biophysics·2026
Same author

Targeted Radionuclide Detection of Malignant Tumors Using Affibody.

Acta naturae·2026
Same author

Targeted Nanoliposomes for the Delivery of Boronophenylalanine into HER2-Positive Cells.

Acta naturae·2025

Related Experiment Video

Updated: Dec 29, 2025

Synthesis, Cellular Delivery and In vivo Application of Dendrimer-based pH Sensors
16:19

Synthesis, Cellular Delivery and In vivo Application of Dendrimer-based pH Sensors

Published on: September 10, 2013

12.1K

DARPins: Promising Scaffolds for Theranostics.

O N Shilova1, S M Deyev1

  • 1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow.

Acta Naturae
|January 30, 2020
PubMed
Summary

Engineered proteins called DARPins offer advantages over traditional monoclonal antibodies for targeted therapies. Their small size, stability, and ease of production make them promising for developing new therapeutic and imaging agents.

Keywords:
DARPinbarnasetargeted therapy

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

960
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

14.9K

Related Experiment Videos

Last Updated: Dec 29, 2025

Synthesis, Cellular Delivery and In vivo Application of Dendrimer-based pH Sensors
16:19

Synthesis, Cellular Delivery and In vivo Application of Dendrimer-based pH Sensors

Published on: September 10, 2013

12.1K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

960
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

14.9K

Area of Science:

  • Biotechnology
  • Protein Engineering
  • Drug Discovery

Background:

  • Monoclonal antibodies are established for targeted therapy.
  • Alternative non-immunoglobulin binding proteins are emerging as targeting modules.
  • DARPins (Designed Ankyrin Repeat Proteins) are a class of engineered scaffold proteins.

Purpose of the Study:

  • To review recent advancements in therapeutic and imaging agents based on DARPins.
  • To highlight the advantages of DARPins compared to traditional antibodies.
  • To discuss the potential of DARPins in developing novel bispecific and multivalent constructs.

Main Methods:

  • Review of recent scientific literature on DARPin development.
  • Analysis of structural and functional properties of DARPins.
  • Comparison of DARPin characteristics with monoclonal antibodies.

Main Results:

  • DARPins exhibit superior stability across a range of temperatures and pH.
  • DARPins demonstrate low aggregation tendencies and are easily produced in expression systems.
  • The unique paratope structure of DARPins expands the range of targetable molecules.
  • Fusion protein technology enables the creation of bispecific and multivalent DARPin constructs.

Conclusions:

  • DARPins present a viable and advantageous alternative to antibodies for targeted therapies.
  • The versatility of DARPins facilitates the development of innovative therapeutic and diagnostic tools.
  • Further research into DARPin-based compounds holds significant promise for future medical applications.